Drug intelligence / Profile preview

Rx Princeps

Development stage: Preclinical
Lead developer: Tetra Bio-Pharma
Administration: Inhalation

Overview

**Rx Princeps** is a standardized prescription medical-cannabis product developed by Tetra Bio-Pharma with Aphria, consisting of a dried blend of three medical cannabis strains with lot-to-lot standardization of its principal cannabinoids, tetrahydrocannabinol and cannabidiol. It was supplied in Canada under the Access to Cannabis for Medical Purposes Regulations and positioned as an inhaled cannabinoid-based option for patients with chronic pain. The same cannabis blend was used in Tetra Bio-Pharma's PPP001 clinical-development program. ([agoracom.com](https://agoracom.com/ir/TetraBio-Pharma/forums/discussion/topics/700763-tetra-bio-pharma-inc-rx-princeps-tm-now-available-for-patients-through-licensed-producer-partner-aphria/messages/2177305))

Brand names: Rx Princeps

Beyond the preview

Go deeper on Rx Princeps.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rx Princeps.

Explore the full profile